Cannabis company Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) has beaten its revenue estimate by $4.38 million, reaching $312.2 million in the second quarter of 2021. That's a 20% sequential and 166% year-over-year pop in revenue. According to Seeking Alpha, GAAP Diluted earnings per share were negative $0.01, missing estimates by $0.01.
"July saw the introduction of the most comprehensive cannabis reform ever proposed at the Federal level," Boris Jordan, the company's executive chairman, disclosed Monday. "Combined with U.S. state-level liberalization and the significant investments we are making in cultivation, production, and distribution, Curaleaf is creating a strong foundation for future growth."
In addition, Curaleaf also remains one of Cantor Fitzgerald's Pablo Zuanic top U.S. picks. The analyst believes that even without the approval of Senate Majority Leader Chuck Schumer's cannabis legalization bill, the U.S. multi-state operators will continue to benefit from ever-increasing sales growth driven by more and more states legalizing cannabis.
Q2 2021 Financial Highlights
- U.S. operations posted revenue of $307 million, …